# Cooper Companies, Inc.: overview

COO · Nasdaq · CIK 711404 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/coo.md) · [Financials](/companies/coo/financials.md) · [Filings](/companies/coo/filings.md) · [Insiders](/companies/coo/insiders.md)

Latest reported revenue: [$1.07bn](/filings/0001628280-26-061160.md) for Q3 FY2026, three months to 2026-07-31, from the 10-Q filed Sep 9, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-061160).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,018 d](/filings/0001628280-25-055615.md) | [965](/filings/0001628280-26-015620.md) | [1,002](/filings/0001628280-26-041305.md) | [1,060](/filings/0001628280-26-061160.md) | [1,065 d](/filings/0001628280-25-055615.md) | [1,024](/filings/0001628280-26-015620.md) | [1,082](/filings/0001628280-26-041305.md) | [1,066](/filings/0001628280-26-061160.md) |
| Gross margin | % | [66.5% d](/filings/0001628280-25-055615.md) | [68.4%](/filings/0001628280-26-015620.md) | [67.8%](/filings/0001628280-26-041305.md) | [65.3%](/filings/0001628280-26-061160.md) | [61.1% d](/filings/0001628280-25-055615.md) | [67.9%](/filings/0001628280-26-015620.md) | [68.0%](/filings/0001628280-26-041305.md) | [66.8%](/filings/0001628280-26-061160.md) |
| Operating margin | % | [19.5% d](/filings/0001628280-25-055615.md) | [18.9%](/filings/0001628280-26-015620.md) | [18.4%](/filings/0001628280-26-041305.md) | [16.6%](/filings/0001628280-26-061160.md) | [13.2% d](/filings/0001628280-25-055615.md) | [20.8%](/filings/0001628280-26-015620.md) | [(2.9%)](/filings/0001628280-26-041305.md) | [20.8%](/filings/0001628280-26-061160.md) |
| Net margin | % | [11.5% d](/filings/0001628280-25-055615.md) | [10.8%](/filings/0001628280-26-061160.md) | [8.7%](/filings/0001628280-26-061160.md) | [9.3%](/filings/0001628280-26-061160.md) | [7.9% d](/filings/0001628280-25-055615.md) | [12.8%](/filings/0001628280-26-061160.md) | [(7.2%)](/filings/0001628280-26-061160.md) | [40.6%](/filings/0001628280-26-061160.md) |
| Diluted EPS | $ per share | not reported | [0.52](/filings/0001628280-26-015620.md) | [0.44](/filings/0001628280-26-041305.md) | [0.49](/filings/0001628280-26-061160.md) | not reported | [0.66](/filings/0001628280-26-015620.md) | [(0.40)](/filings/0001628280-26-041305.md) | [2.24](/filings/0001628280-26-061160.md) |
| Free cash flow | $m | [128 d](/filings/0001628280-25-055615.md) | [101](/filings/0001628280-26-015620.md) | [18.1 d](/filings/0001628280-26-041305.md) | [165 d](/filings/0001628280-26-061160.md) | [150 d](/filings/0001628280-25-055615.md) | [159](/filings/0001628280-26-015620.md) | [96.4 d](/filings/0001628280-26-041305.md) | [273 d](/filings/0001628280-26-061160.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-10-31) | FY2022 (2022-10-31) | FY2023 (2023-10-31) | FY2024 (2024-10-31) | FY2025 (2025-10-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,923](/filings/0000711404-23-000072.md) | [3,308](/filings/0000711404-24-000074.md) | [3,593](/filings/0001628280-25-055615.md) | [3,895](/filings/0001628280-25-055615.md) | [4,092](/filings/0001628280-25-055615.md) |
| Gross margin | % | [66.9%](/filings/0000711404-23-000072.md) | [64.7%](/filings/0000711404-24-000074.md) | [65.6%](/filings/0001628280-25-055615.md) | [66.6%](/filings/0001628280-25-055615.md) | [65.5%](/filings/0001628280-25-055615.md) |
| Operating margin | % | [17.3%](/filings/0000711404-23-000072.md) | [15.3%](/filings/0000711404-24-000074.md) | [14.8%](/filings/0001628280-25-055615.md) | [18.1%](/filings/0001628280-25-055615.md) | [16.7%](/filings/0001628280-25-055615.md) |
| Net margin | % | [100.8%](/filings/0000711404-23-000072.md) | [11.7%](/filings/0000711404-24-000074.md) | [8.2%](/filings/0001628280-25-055615.md) | [10.1%](/filings/0001628280-25-055615.md) | [9.2%](/filings/0001628280-25-055615.md) |
| Diluted EPS | $ per share | [59.16](/filings/0000711404-23-000072.md) | [1.94](/filings/0000711404-24-000074.md) | [1.48](/filings/0001628280-25-055615.md) | [1.96](/filings/0001628280-25-055615.md) | [1.87](/filings/0001628280-25-055615.md) |
| Free cash flow | $m | [524](/filings/0000711404-23-000072.md) | [450](/filings/0000711404-24-000074.md) | [215](/filings/0001628280-25-055615.md) | [288](/filings/0001628280-25-055615.md) | [434](/filings/0001628280-25-055615.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/coo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.08bn | 15,029,453 |  | Reduced −1,588,676 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $914.9m | 12,758,769 |  | Added +39,940 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $637.7m | 8,892,643 |  | Added +124,224 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $621.7m | 8,669,690 |  | Reduced −51,641 |
| [BROWNING WEST LP](/funds/1825564.md) | 2026-06-30 | $516.0m | 7,195,428 |  | Added +215,899 |
| [KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC](/funds/1021223.md) | 2026-06-30 | $389.4m | 5,430,282 |  | Reduced −1,186,395 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $382.9m | 5,359,812 |  | Added +48,289 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $365.5m | 5,096,888 |  | Added +229,606 |
| [GENERATION INVESTMENT MANAGEMENT LLP](/funds/1375534.md) | 2026-06-30 | $356.3m | 4,968,673 |  | Added +369,284 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $305.1m | 4,254,267 |  | Not compared |

## Recent filings

[All 1,372 filings](/companies/coo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-09 | 16:48 ET | [10-Q](/filings/0001628280-26-061160.md) | Quarterly report, period 2026-07-31 | 0001628280-26-061160 |
| 2026-09-09 | 16:34 ET | [8-K](/filings/0001628280-26-061155.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-061155 |
| 2026-06-05 | 16:47 ET | [10-Q](/filings/0001628280-26-041305.md) | Quarterly report, period 2026-04-30 | 0001628280-26-041305 |
| 2026-06-04 | 16:27 ET | [8-K](/filings/0001628280-26-040823.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-040823 |
| 2026-05-04 | 16:30 ET | [8-K](/filings/0001628280-26-029853.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-029853 |
| 2026-04-08 | 16:53 ET | [8-K](/filings/0001628280-26-024273.md) | 5.07 Shareholder vote results | 0001628280-26-024273 |
| 2026-03-06 | 16:12 ET | [10-Q](/filings/0001628280-26-015620.md) | Quarterly report, period 2026-01-31 | 0001628280-26-015620 |
| 2026-03-05 | 16:27 ET | [8-K](/filings/0001628280-26-015231.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-015231 |
| 2026-02-24 | 16:19 ET | [DEF 14A](/filings/0001628280-26-011110.md) | Proxy statement, period 2026-04-07 | 0001628280-26-011110 |
| 2026-02-04 | 21:58 ET | [8-K](/filings/0001193125-26-036476.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-036476 |

## Latest annual report

[Form 10-K for the fiscal year ended Oct 31, 2025](/filings/0001628280-25-055615.md), filed Dec 5, 2025.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 711404
- Tickers: COO
- Exchange: Nasdaq
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:37 ET. No prices; not investment advice.